Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 November 2022 | Story Andre Damons | Photo Supplied
Thaba Nchu health web new
One Health Warriors with the scholar pledge cloth after scholars made a pledge to take care of their pets at St Paul’s Primary School in Thaba Nchu.

International One Health Day is held annually on 3 November. The goal of the day is to educate and increase awareness of One Health to encourage a collaborative effort between multiple disciplines, promoting the concept that the interactions between humans, animals, and the environment impact the health of people, animals, plants, and the environment.

The aptly named One Health Warriors, a student group comprising postgraduate students from the Division of Virology at the University of the Free State (UFS), was formed in 2016. The One Health Warriors annually participate in arranging a One Health event to celebrate International One Health Day. What is One Health? What zoonotic diseases should the public be aware of? How do zoonoses affect the healthcare provider? These are all questions that the student group addresses in their events.  

In 2022, the One Health Warriors targeted scholars to participate in their annual event. It is important for scholars to start learning about One Health from an early age, because most of them do not understand the importance of taking care of their pets. They are not always aware of the diseases that can be transmitted from animals to humans and how to protect themselves.

It is for this reason that postgraduate students from the Division of Virology took One Health awareness and science communication to the classrooms of Ratau Primary and St. Pauls Primary schools in Thaba Nchu, Bloemfontein. Grade 6 scholars were included in the events and a total of 224 learners participated in the day. 

According to Prof Felicity Burt, an expert in arbovirology in the Division of Virology and the National Health Laboratory Services (NHLS) – who holds an NRF-DST South African Research Chair in Vector-borne and Zoonotic Pathogens Research – and Tumelo Sekee, PhD student and research assistant in the School of Pathology, they decided to start with primary schools as they believe it is good to start teaching scholars from an early age to take care of their pets and understand the importance of One Health. 

Making the youth aware 

The focus was on making the youth aware of diseases transmitted from animals to humans, how to protect themselves from zoonotic diseases, and how to take care of their pets. They used role-play activities in which the learners were educated about the risk of contracting the rabies virus and some of the signs that may be shown by rabid dogs. The learners also got to learn about the importance of reporting any bites and getting appropriate treatment from the clinics.  

Rabies circulates within this area and is a high risk for children who play with stray dogs. They were advised about vaccines to protect their dogs against infection and thereby protecting themselves. They were shown how to remove ticks from the dogs, and the importance of not eating a dead animal whose cause of death is unknown. 

“The children were advised on the potential for tuberculosis (TB bovis) to occur in their livestock and the potential for spread to humans. Pictures were circulated among the learners showing them what a rabid dog or animal might look like and how an animal with TB bovis may present. The learners were taught about the importance of hand washing. In the finale of the event, the learners made a pledge to take care of their pets, and this was confirmed with painted hands on our One Health posters,” says Tumelo Sekee.

According to Prof Burt, One Health is an approach that recognises that the health of people is closely connected to the health of animals and their shared environment. One Health is not new, but it has become more important in recent years. “This is partly because many factors have influenced the way humans interact with animals (domestic and wild), plants, and our environment. These changes have led to the spread of known (endemic) pathogens and the emergence of novel pathogens and zoonotic diseases, which are diseases that can spread between animals and people. The recent pandemic is an example of how zoonotic transmission of a pathogen from wildlife to humans has a devastating public health impact,” explains Prof Burt.

Positive feedback
Sekee says the feedback was extremely positive; this may be because the communication was done in the learners’ mother tongue, Setswana, which made it easy for them to understand. Says Sekee: “There were many questions and discussions after the play, which suggested that the scholars showed interest in learning about a One Health approach. The scholars were also enthusiastic about participating in future events of the One Health warriors.”

The postgraduate One Health group previously also visited schools in Botshabelo and Bloemfontein, as well as farm workers in Kroonstad. They now plan to visit other schools in the Free State so that the One Health message can reach as many people as possible.  

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept